Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.3%

1 terminated/withdrawn out of 19 trials

Success Rate

93.8%

+7.2% vs industry average

Late-Stage Pipeline

37%

7 trials in Phase 3/4

Results Transparency

27%

4 of 15 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 2

6(33.3%)

Phase 3

4(22.2%)

N/A

3(16.7%)

Phase 4

3(16.7%)

Early Phase 1

2(11.1%)

18Total

Phase 2(6)

Phase 3(4)

N/A(3)

Phase 4(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT02733185Phase 3Completed

Trial to Assess Chelation Therapy 2

Role: lead

NCT03982693Phase 3Recruiting

Trial to Assess Chelation Therapy in Critical Limb Ischemia

Role: lead

NCT02075554Not ApplicableCompleted

Study of an Expandable Interbody Device for the Lumbar Spine

Role: collaborator

NCT04629560Early Phase 1Completed

Miracle Fruit Powder for the Treatment of Taste Alterations Secondary to Chemotherapy

Role: lead

NCT01999517Phase 4Completed

Contrast Nephropathy and Nitrates

Role: lead

NCT03424746Early Phase 1Completed

Chelation Therapy in Diabetic Patients With Critical Limb Ischemia

Role: lead

NCT02421029Phase 4Withdrawn

Prolonged Gadolinium Retention After MRI Imaging

Role: lead

NCT03199378Unknown

Neuropsychological Norms for Ethnically Diverse Florida Elders

Role: collaborator

NCT01844622Not ApplicableCompleted

Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying

Role: lead

NCT00000561Phase 3Completed

Mode Selection Trial in Sinus Node Dysfunction (MOST)

Role: lead

NCT02087618Not ApplicableUnknown

The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment

Role: lead

NCT00044213Phase 3Completed

Trial to Assess Chelation Therapy (TACT)

Role: lead

NCT00682383Phase 2Completed

Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT00616564Phase 2Completed

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

Role: lead

NCT00483301Phase 2Completed

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

Role: lead

NCT01048554Phase 2Completed

Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System

Role: lead

NCT00625573Phase 2Completed

Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)

Role: lead

NCT00217282Phase 2Completed

Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer

Role: lead

NCT00158041Phase 4Completed

Subcutaneous Amifostine Safety Study

Role: lead

All 19 trials loaded